The chart shows the distribution of publications by all Research.com ranked scientists in the field of Biology and Biochemistry in 2026. The highlighted bar marks where Glenn B. Collins sits on this spectrum.
This scientist: 176 publications — 39th percentile
39% of scientists in this discipline score the same or lower.
The last bar groups every scientist with 1,028 publications or more.
The chart shows the D-index (discipline H-index) distribution of Biology and Biochemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Glenn B. Collins sits on this spectrum.
This scientist: 48 D-Index — 7th percentile
7% of scientists in this discipline score the same or lower.
The last bar groups every scientist with 167 D-Index or more.
Glenn B. Collins is affiliated with the University of Kentucky in the United States. Their research primarily focuses on biochemistry, genetics, and molecular biology, contributing notably to subfields such as molecular biology, epidemiology, cell biology, genetics, and physiology.
The main topics of Collins's work cover ubiquitin and proteasome pathways, autophagy in disease and therapy, endoplasmic reticulum stress and disease, genetics and neurodevelopmental disorders, protein degradation and inhibitors, Alzheimer's disease research and treatments, and GDF15 and related biomarkers.
Frequent coauthors in Collins's publications include Alfred L. Goldberg, Shan Jiang, M. Srikanth, Shadi Yavari, and Pallavi Gaur.
Collins has published papers in several scientific venues, with notable repeated contributions to the Proceedings of the National Academy of Sciences. Other publication venues include Biomolecules, the Journal of Biological Chemistry, Brain, and Human Molecular Genetics.
Collins's research intersects extensively with mechanisms of protein degradation, proteasome activation, and their implications in neurological diseases such as Alzheimer's disease. The scientist's work contributes to understanding the molecular pathways regulating proteostasis and how their dysfunction can drive disease progression.
Throughout their career, Collins has engaged with topics that bridge molecular biology and medicine, reflecting an interdisciplinary approach to understanding cellular degradation systems and their broader biological impacts.
Gregory C. Phillips;G. B. Collins
Paul A. Lazzeri;David F. Hildebrand;Glenn B. Collins
W. A. Parrott;L. M. Hoffman;D. F. Hildebrand;E. G. Williams
Rong Di;Virginia Purcell;Glenn B. Collins;Said A. Ghabrial
Paul A. Lazzeri;David F. Hildebrand;Glenn B. Collins
W. A. Parrott;G. Dryden;S. Vogt;D. F. Hildebrand
C. A. Meurer;R. D. Dinkins;G. B. Collins
W. Liu;W. A. Parrott;D. F. Hildebrand;G. B. Collins
Venkata S. Tavva;Yul-Ho Kim;Isabelle A. Kagan;Randy D. Dinkins
Paul A. Lazzeri;David F. Hildebrand;Glenn B. Collins
Randy D. Dinkins;M. S. Srinivasa Reddy;Curtis A. Meurer;Bo Yan
W. A. Parrott;E. G. Williams;D. F. Hildebrand;G. B. Collins
Randy D. Dinkins;M. S. Srinivasa Reddy;Curtis A. Meurer;Carl T. Redmond
B. Yan;M. S. Srinivasa Reddy;G. B. Collins;R. D. Dinkins
L. M. Hartweck;P. A. Lazzeri;D. Cui;G. B. Collins
John Fellers;Jinrong Wan;Yiling Hong;Glenn B. Collins
Mark L. Dahmer;Pierce D. Fleming;Glenn B. Collins;David F. Hildebrand
Wilfried Kysely;James R. Myers;Paul A. Lazzeri;Glenn B. Collins
Paul D. Legg;G. B. Collins
M. S. Srinivasa Reddy;Randy D. Dinkins;Glenn B. Collins
If you think any of the details on this page are incorrect, let us know.